



# Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years

Sabine Kürzel<sup>1</sup> · André-René Blaudszun<sup>2</sup> · Lilly Stahl<sup>2</sup> · Regina Herbst<sup>3</sup> · Frank Kroschinsky<sup>4</sup> · Josef Birkmann<sup>5</sup> · Annette Hänel<sup>3</sup> · Kerstin Schaefer-Eckart<sup>5</sup> · Gerhard Ehninger<sup>4</sup> · Friedrich Fiedler<sup>3</sup> · Martin Bornhäuser<sup>4</sup> · Stephan Fricke<sup>2,3</sup> · Mathias Hänel<sup>3</sup>

Published online: 9 September 2022

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

**Correction:**  
**Journal of Cancer Research and Clinical Oncology**  
**(2022) 148:1171–1181**  
<https://doi.org/10.1007/s00432-021-03702-7>

Fig. 2(b)

Published values:

	MIFAP	DexaBEAM
Median PFS, months (95% CI)	0.28 (0.72 – 26.2)	3.83
HR (95% CI) (compared with DexaBEAM)	0.88	

Corrected values:

	MIFAP	DexaBEAM
Median PFS, months (95% CI)	3.83 (0.07 – 26.2)	0.28

The original article can be found online at <https://doi.org/10.1007/s00432-021-03702-7>.

✉ Mathias Hänel  
m.haenel@skc.de

<sup>1</sup> Medical Clinic 5, Klinikum Dresden-Neustadt, Dresden, Germany

<sup>2</sup> Department of GMP Process Development/ATMP Design, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany

<sup>3</sup> Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Flemmingstrasse 1, 09116 Chemnitz, Germany

<sup>4</sup> Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU, Dresden, Germany

<sup>5</sup> Klinikum Nuernberg, Paracelsus Medical Private University, Medical Clinic 5, Nuremberg, Germany

	MIFAP	DexaBEAM
HR (95% CI) (compared with DexaBEAM)	0.87	

Fig. 2(c)

Published values:

	DexaBEAM
Survival at 5 years, % (95% CI)	47.9
Survival at 10 years, % (95% CI)	47.9
Survival at 15 years, % (95% CI)	47.9

Corrected values:

	DexaBEAM
Survival at 5 years, % (95% CI)	76.9
Survival at 10 years, % (95% CI)	76.9
Survival at 15 years, % (95% CI)	76.9


Fig. 2(d)

Published value:


	MIFAP
Survival at 15 years, % (95% CI)	8.3

Corrected value:


	MIFAP
Survival at 15 years, % (95% CI)	8.2




	MIFAP (n = 12)	DexaBEAM (n = 13)
Median PFS, months (95% CI)	5.52 (0.72 – NA)	41.82 (0.13 – NA)
HR (95% CI) (compared with DexaBEAM)	1.34 (0.48 – 3.74)	
P value	P = 0.54	
Survival at 5 years, % (95% CI)	33.3 (15.0 – 74.2)	46.2 (25.7 – 83.0)
Survival at 10 years, % (95% CI)	33.3 (15.0 – 74.2)	46.2 (25.7 – 83.0)
Survival at 15 years, % (95% CI)	NA	46.2 (25.7 – 83.0)



	MIFAP (n = 24)	DexaBEAM (n = 24)
Median PFS, months (95% CI)	3.83 (0.07 – 26.2)	0.28 (0.07 – 12.6)
HR (95% CI) (compared with DexaBEAM)	0.87 (0.46 – 1.66)	
P value	P = 0.68	
Survival at 5 years, % (95% CI)	18.2 (7.6 – 43.8)	18.3 (7.6 – 44.0)
Survival at 10 years, % (95% CI)	18.2 (7.6 – 43.8)	18.3 (7.6 – 44.0)
Survival at 15 years, % (95% CI)	NA	18.3 (7.6 – 44.0)



	MIFAP (n = 12)	DexaBEAM (n = 13)
Median OS, months (95% CI)	33.0 (11.6 – NA)	NA
HR (95% CI) (compared with DexaBEAM)	2.83 (0.7 – 11.41)	
P value	P = 0.13	
Survival at 5 years, % (95% CI)	47.6 (25.7 – 88.2)	76.9 (57.1 – 100.0)
Survival at 10 years, % (95% CI)	47.6 (25.7 – 88.2)	76.9 (57.1 – 100.0)
Survival at 15 years, % (95% CI)	47.6 (25.7 – 88.2)	76.9 (57.1 – 100.0)



	MIFAP (n = 24)	DexaBEAM (n = 24)
Median OS, months (95% CI)	23.5 (8.61 – 78.0)	10.3 (5.62 – 29.1)
HR (95% CI) (compared with DexaBEAM)	0.85 (0.45 – 1.59)	
P value	P = 0.61	
Survival at 5 years, % (95% CI)	27.5 (14.1 – 53.6)	22.0 (10.2 – 47.6)
Survival at 10 years, % (95% CI)	16.5 (6.2 – 43.9)	22.0 (10.2 – 47.6)
Survival at 15 years, % (95% CI)	8.2 (1.5 – 45.0)	22.0 (10.2 – 47.6)

◀**Fig. 2** Kaplan–Meier curves showing PFS from Dexa-BEAM for HL ( $N=13$ ) vs. MIFAP ( $N=12$ ) for HL (**a**) and PFS for Dexa-BEAM ( $N=24$ ) for NHL vs. MIFAP ( $N=24$ ) for NHL (**b**), OS from Dexa-BEAM for HL ( $N=13$ ) vs. MIFAP ( $N=12$ ) for HL (**c**) and OS from Dexa-BEAM ( $N=24$ ) for NHL vs. MIFAP ( $N=24$ ) for NHL (**d**), *HR* hazard ratio

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.